Show simple item record

dc.contributor.authorLanario, J
dc.contributor.authorCartwright, L
dc.contributor.authorJones, R
dc.contributor.authorSayers, R
dc.contributor.authorHyland, M
dc.contributor.authorMasoli, M
dc.date.accessioned2022-11-14T16:26:21Z
dc.date.issued2022-11-28
dc.identifier.issn1471-2466
dc.identifier.issn1471-2466
dc.identifier.other445
dc.identifier.urihttp://hdl.handle.net/10026.1/19970
dc.description.abstract

Background There is limited information on the patient’s perspective of how biologic treatments impact their lives. We conducted a qualitative study to explore the patient’s experience of being considered a super-responder from a quality of life perspective.

Methods Patients with severe asthma identified as super-responders were invited to semi-structured interviews conducted online. Participants could bring a family member/friend to the interview. The interviews explored experiences of biologic treatment, were transcribed and underwent thematic analysis.

Results Twenty-five participants took part in this study. Themes emerged on the impact of biologic treatment for participants and for their friends/family: (i) Words used to describe their often life-changing experiences and (ii) the positive changes noted. Biologic treatment stopped the disruption of family life and social life caused by exacerbations. Improvements in mental health were also noted. Marked individual variations in the way it affected their lives were noted. Most participants noticed improvements 2–3 months after starting their biologic, but some noticed improvement within a few days and others after 6 months.

Conclusions Super-responders reported profound but heterogeneous improvements following biologic treatment beyond asthma symptoms and exacerbations including important benefits to social and family life. Improvements may be underestimated as social and family benefits are not reliably measured in current studies with implications for health economic evaluations. Not all patients are super-responders, and excellent responses may be lost in group mean data in trials. Individual time course and response patterns need further elucidation to identify who will respond best to biologics.

dc.description.sponsorship
dc.format.extent445-
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherBioMed Central
dc.subjectSevere asthma
dc.subjectQoL
dc.subjectPatient perspectives
dc.subjectQualitative
dc.subjectBiologics
dc.subjectSuper-responders
dc.title"Life-changing”- the experience of super-responders to biologics in severe asthma
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36437459
plymouth.issue1
plymouth.volume22
plymouth.publisher-urlhttp://dx.doi.org/10.1186/s12890-022-02241-2
plymouth.publication-statusPublished online
plymouth.journalBMC Pulmonary Medicine
dc.identifier.doi10.1186/s12890-022-02241-2
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2022-11-14
dc.rights.embargodate2022-11-30
dc.identifier.eissn1471-2466
dc.rights.embargoperiod
rioxxterms.versionofrecord10.1186/s12890-022-02241-2
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV